Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun;18(3):119-25.
doi: 10.3747/co.v18i3.751.

Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres

Y Madarnas  1 , S F Dent, S F Husain, A Robinson, S Alkhayyat, W M Hopman, J L Verreault, T Vandenberg
Affiliations

Real-world experience with adjuvant fec-d chemotherapy in four Ontario regional cancer centres

Y Madarnas et al. Curr Oncol. 2011 Jun.

Abstract

Background: The efficacy of adjuvant chemotherapy with fec-d (5-fluorouracil-epirubicin-cyclophosphamide followed by docetaxel) is superior to that with fec-100 alone in women with early-stage breast cancer. As the use of fec-d increased in clinical practice, health care providers anecdotally noted higher-than-expected toxicity rates and frequent early treatment discontinuations because of toxicity. In the present study, we compared the rates of serious adverse events in patients who received adjuvant fec-d chemotherapy in routine clinical practice with the rates reported in the pacs-01 trial.

Methods: We retrospectively reviewed all patients prescribed adjuvant fec-d for early-stage breast cancer at 4 regional cancer centres in Ontario. Information was collected from electronic and paper charts by a physician investigator from each centre. Data were analyzed using chi-square tests, independent samples t-tests, one-way analysis of variance, and univariate regression.

Results: The 671 electronic and paper patient records reviewed showed a median patient age of 52.2 years, 229 patients (34.1%) with N0 disease, 508 patients (75.7%) with estrogen or progesterone receptor-positive disease (or both), and 113 patients (26%) with her2/neu-overexpressing breast cancer. Febrile neutropenia occurred in 152 patients (22.7%), most frequently at cycle 4, coincident with the initiation of docetaxel [78/152 (51.3%)]. Primary prophylaxis with hematopoietic growth factor support was used in 235 patients (35%), and the rate of febrile neutropenia was significantly lower in those who received prophylaxis than in those who did not [15/235 (6.4%) vs. 137/436 (31.4%); p < 0.001; risk ratio: 0.20].

Conclusions: In routine clinical practice, treatment with fec-d is associated with a higher-than-expected rate of febrile neutropenia, in light of which, primary prophylaxis with growth factor should be considered, per international guidelines. Adoption based on clinical trial reports of new therapies into mainstream practice must be done carefully and with scrutiny.

Keywords: Febrile neutropenia; breast cancer; fec-d chemotherapy; growth factor; toxicity.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Rates of febrile neutropenia by cycle of chemotherapy in women with early-stage breast cancer at 4 Ontario cancer centres. fec = 5-fluorouracil–epirubicin–cyclophosphamide.
FIGURE 2
FIGURE 2
Rates of febrile neutropenia by age group and growth factor use in women with early-stage breast cancer at 4 Ontario cancer centres. p < 0.001 by Pearson chi-square test.
See this image and copyright information in PMC

References

    1. Canadian Cancer Society’s Steering Committee . Canadian Cancer Statistics 2009. Toronto, ON: Canada Cancer Society; 2009.
    1. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med. 1976;294:405–10. doi: 10.1056/NEJM197602192940801. - DOI - PubMed
    1. Fisher B, Carbone P, Economou SG, et al. l-Phenylalanine mustard (l-pam) in the management of primary breast cancer: a report of early findings. N Engl J Med. 1975;292:117–22. doi: 10.1056/NEJM197501162920301. - DOI - PubMed
    1. Early Breast Cancer Trialists’ Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–717. - PubMed
    1. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1998;8:2651–8. - PubMed